BeiGene Co.,Ltd

350 articles with BeiGene Co.,Ltd

• 

  BeiGene, Lexicon and 9 Meters Wrap First Half with Clinical Wins

  6/30/2022

  Capping off the first half of the year is a flurry of clinical trial wins. BioSpace takes a look at some of the most exciting ones:

• BeiGene Announces Late-Breaking Data at ESMO GI Showing Overall Survival Benefit for Tislelizumab Plus Chemotherapy in First-Line Advanced or Metastatic Esophageal Squamous Cell Carcinoma

  6/30/2022

  BeiGene announced new data from RATIONALE 306, a global Phase 3 trial evaluating tislelizumab plus chemotherapy in adult patients with advanced or metastatic esophageal squamous cell carcinoma without prior systemic treatment for advanced disease.

• Antengene Announces Clinical Trial Collaboration with BeiGene to Evaluate Selinexor in Combination with Tislelizumab in T and NK-Cell Lymphoma

  6/27/2022

  Antengene Corporation Limited announced that it has entered into a clinical trial collaboration with BeiGene to evaluate the safety, pharmacokinetics, pharmacodynamics and preliminary efficacy of selinexor in combination with BeiGene's anti-PD-1 checkpoint inhibitor, tislelizumab.

• BeiGene Announces Acceptance of Supplemental Biologics License Application in China for Anti-PD-1 Inhibitor Tislelizumab

  6/21/2022

  Submission seeks marketing authorization for use with chemotherapy as first-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma whose tumor expresses PD-L1.

• BeiGene Announces BRUKINSA™ (zanubrutinib) Is Approved in 50 Markets

  6/13/2022

  BeiGene Announces BRUKINSA ™ (zanubrutinib) Is Approved in 50 Markets.

• BeiGene Announces PDUFA Goal Date Extension for U.S. sNDA for BRUKINSA for the Treatment of CLL/SLL

  6/13/2022

  Following Additional Data Submission to FDA Demonstrating ORR Superiority Over Ibrutinib As Determined by IRC, PDUFA Goal Date Extended to January 20, 2023 to Allow Time for Review.

• China NMPA Approves Tislelizumab for Recurrent or Metastatic Nasopharyngeal Cancer

  6/10/2022

  Tislelizumab is now approved in nine indications in China.

• BeiGene Highlights Growing Portfolio and Pipeline Targeting Hematologic Malignancies at European Hematology Association 2022 Congress

  6/10/2022

  Clinical data and patient-reported outcomes across extensive clinical development program for zanubrutinib (BRUKINSA ® ) reinforce its potential across B-cell malignancies.

• BeiGene to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference

  6/8/2022

  BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, today announced that Julia Wang, Chief Financial Officer, and Angus Grant, Ph.D., Chief Business Executive, will participate in a fireside chat at the Goldman Sachs Conference.

• 

  All Blue Ups the Ante after Zymeworks Rejects Bid

  5/27/2022

  Zymeworks increased its stake in the company to 6.9%, slightly under 4 million shares, and options with shares popped 13% after the original bid and are up another 10%.

• BeiGene Clinical Data Presentations at 2022 ASCO Annual Meeting Demonstrate Mature and Growing Oncology Portfolio

  5/26/2022

  BeiGene will present data from its broad solid tumor and hematology portfolios in eight presentations at the upcoming American Society of Cancer Oncology Annual Meeting being held in Chicago from June 3-7, 2022.

• BeiGene Strengthens European Presence With the Opening of Regional Office in Basel, Switzerland

  5/17/2022

  BeiGene, Ltd., a global biotechnology company focused on developing and commercializing innovative medicines worldwide, yesterday announced the opening of a new regional office in Basel, Switzerland.

• 

  iTeos and GSK Mull Future of Anti-TIGIT Candidate After Genentech Flop

  5/13/2022

  Genentech's flop of its anti-TIGIT drug has cast a shadow of doubt over the numerous companies in the process of developing their own anti-TIGIT drugs.

• BeiGene to Demonstrate Strength of Hematology Portfolio and Pipeline at European Hematology Association 2022 Congress

  5/12/2022

  BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, today announced 20 presentations from the Company’s global clinical development programs in hematologic malignancies at the European Hematology Association (EHA) 2022 Hybrid Congress.

• 

  SEC Tightens Screws on Chinese Companies with Delisting Efforts

  5/6/2022

  The U.S. SEC continues to tighten the screws on Chinese companies, adding more than 80 companies to its expanding list of companies that might be dropped from U.S. stock exchanges.
• 

  BeiGene Reports Lucrative Q1 Amid SEC Audit

  5/6/2022

  Despite a growing product revenue, Beigene reported a net loss of $434.4 million for the first quarter of 2022, as well as updates to its audit from the SEC.

• BeiGene Reports First Quarter 2022 Financial Results

  5/5/2022

  BeiGene, Ltd. today reported financial results for the first quarter of 2022, recent business highlights, and anticipated upcoming milestones.

• BeiGene Announces the Approval in China of BLINCYTO® (Blinatumomab) for Injection for Pediatric Patients with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (ALL)

  5/4/2022

  BeiGene announced that the China National Medical Products Administration has granted conditional approval of BLINCYTO® for injection for the treatment of pediatric patients with relapsed or refractory CD19-positive B-cell precursor acute lymphoblastic leukemia.

• BeiGene Breaks Ground on New Manufacturing and Clinical R&D Center at the Princeton West Innovation Campus in New Jersey

  4/29/2022

  BeiGene, Ltd. announced the groundbreaking of its flagship U.S. manufacturing and clinical R&D center at the Princeton West Innovation Campus in Hopewell, N.J.

• 

  Zymeworks Mulls $733 Million Bid from All Blue Capital

  4/29/2022

  Zymeworks received an unsolicited, non-binding acquisition offer from global investment firm All Blue Capital. All Blue is offering $10.50 per share for a total of $773 million in cash.